$BMRN BIOMARIN PHARMACEUTICAL INC Insider Trading Week 11/2018
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in BIOMARIN PHARMACEUTICAL INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in BIOMARIN PHARMACEUTICAL INC in week 11/2018.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 23 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Sell | S | 83.90 | 4,368 | 366,475 | 60,153 | 64.5 K to 60.2 K (-6.77 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 15,000 | 578,850 | 142,500 | |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 83.26 | 15,000 | 1,248,854 | 296,106 | 311.1 K to 296.1 K (-4.82 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 15,000 | 578,850 | 311,106 | 296.1 K to 311.1 K (+5.07 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Sell | S | 83.88 | 3,818 | 320,254 | 94,634 | 98.5 K to 94.6 K (-3.88 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Option Exercise | A | 83.57 | 9,120 | 762,158 | 9,120 | |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Grant | A | 0.00 | 5,710 | 0 | 17,973 | 12.3 K to 18 K (+46.56 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 84.10 | 346 | 29,099 | 12,263 | 12.6 K to 12.3 K (-2.74 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | Mueller Brian | SVP, Corporate Cont ... | Payment of Exercise | F | 83.57 | 309 | 25,823 | 12,609 | 12.9 K to 12.6 K (-2.39 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | A | 83.57 | 148,190 | 12,384,238 | 148,190 | |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Option Exercise | M | 38.59 | 15,000 | 578,850 | 157,500 | |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Grant | A | 0.00 | 46,340 | 0 | 296,106 | 249.8 K to 296.1 K (+18.55 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Payment of Exercise | F | 83.57 | 14,908 | 1,245,862 | 249,766 | 264.7 K to 249.8 K (-5.63 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Sell | S | 84.73 | 15,000 | 1,270,901 | 264,674 | 279.7 K to 264.7 K (-5.36 %) |
| Mar 20 2018 | BMRN | BIOMARIN PHARMACEU ... | BIENAIME JEAN JACQUES | Chief Executive Off ... | Buy | M | 38.59 | 15,000 | 578,850 | 279,674 | 264.7 K to 279.7 K (+5.67 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Option Exercise | A | 83.57 | 38,760 | 3,239,173 | 38,760 | |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Grant | A | 0.00 | 12,120 | 0 | 98,452 | 86.3 K to 98.5 K (+14.04 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | Davis George Eric | EVP, General Counse ... | Payment of Exercise | F | 83.57 | 3,757 | 313,972 | 86,332 | 90.1 K to 86.3 K (-4.17 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Option Exercise | A | 83.57 | 51,300 | 4,287,141 | 51,300 | |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Grant | A | 0.00 | 16,040 | 0 | 162,488 | 146.4 K to 162.5 K (+10.95 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | FUCHS HENRY J | President, Worldwid ... | Payment of Exercise | F | 83.57 | 4,861 | 406,234 | 146,448 | 151.3 K to 146.4 K (-3.21 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Option Exercise | A | 83.57 | 38,760 | 3,239,173 | 38,760 | |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Grant | A | 0.00 | 12,120 | 0 | 87,945 | 75.8 K to 87.9 K (+15.98 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | BAFFI ROBERT | EVP, Technical Oper ... | Payment of Exercise | F | 83.57 | 3,644 | 304,529 | 75,825 | 79.5 K to 75.8 K (-4.59 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Option Exercise | A | 83.57 | 41,040 | 3,429,713 | 41,040 | |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Grant | A | 0.00 | 12,840 | 0 | 64,521 | 51.7 K to 64.5 K (+24.84 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | Ajer Jeffrey Robert | EVP, Chief Commerci ... | Payment of Exercise | F | 83.57 | 3,651 | 305,114 | 51,681 | 55.3 K to 51.7 K (-6.60 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Option Exercise | A | 83.57 | 39,900 | 3,334,443 | 39,900 | |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Grant | A | 0.00 | 12,480 | 0 | 77,185 | 64.7 K to 77.2 K (+19.29 %) |
| Mar 19 2018 | BMRN | BIOMARIN PHARMACEU ... | SPIEGELMAN DANIEL K | EVP, Chief Financia ... | Payment of Exercise | F | 83.57 | 3,815 | 318,820 | 64,705 | 68.5 K to 64.7 K (-5.57 %) |